查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542920

全球败血症诊断市场 - 2024-2031

Global Sepsis Diagnostic Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

2023年，全球败血症诊断市场规模达到7.1013亿美元，预计2031年将达到14.3524亿美元，2024-2031年预测期间复合年增长率为9.5%。

败血症是一种危及生命的疾病，当人体免疫系统对感染反应过度，导致器官功能障碍时，就会发生败血症。身体的反应会损害其组织和器官，如果不及时发现和治疗，可能会导致休克、多重器官衰竭，甚至死亡。

进行血液检查和其他实验室检查（例如尿液、伤口液体、呼吸道黏液和唾液）来诊断病情。

市场动态：

驱动程式和限制

传染病负担日益沉重

如果传染性感染未及时发现和治疗，可能会发展为脓毒症等严重疾病。因此，人们更加重视可能发展为败血症的感染的早期诊断。败血症的诊断测试可帮助医疗保健提供者及早发现病情，从而进行适当的干预和管理。 HAI 是院内感染，可显着导致败血症病例。

随着医疗保健相关感染的持续上升，越来越需要精确的诊断工具来监测患者并在这些环境中及早诊断脓毒症。

在欧洲，就残疾和过早死亡而言，六种最常见的医院感染的负担据计算是其他 32 种传染病负担的两倍。

此外，根据 2023 Balasubramanian 等人发表的研究，全球每年估计发生 1.36 亿例与医疗保健相关的抗生素抗药性感染病例。因此，传染病负担的增加预计将推动市场成长。

诊断工具成本高

自动诊断仪器和生物标记测试可能非常昂贵。高额的前期费用可能会导致医疗机构的整体采用率下降。这直接导致败血症诊断市场成长放缓。儘管有这些限制，医院仍将继续使用较旧的、较便宜的方法。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 传染病负担日益加重
    • 限制
      • 诊断工具成本高
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 报销分析
  • 专利分析
  • SWOT分析
  • DMI 意见

第 6 章：副产品

  • 仪器仪表
  • 软体
  • 血液培养介质
  • 测定和试剂
  • 其他的

第 7 章：按技术

  • 流式细胞仪
  • 微生物学
  • 生物标誌物
  • 分子诊断
  • 微流控
  • 其他的

第 8 章：透过诊断方法

  • 自动诊断
  • 常规诊断

第9章：按病原体

  • 霉菌性败血症
  • 细菌性败血症
    • 革兰氏阳性细菌败血症
    • 革兰氏阴性细菌败血症
  • 其他病原体

第 10 章：最终用户

  • 医院
  • 病理学和参考实验室
  • 其他的

第 11 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 12 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 13 章：公司简介

  • Thermo Fisher Scientific Inc.
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Bruker Corporation
  • Merck Millipore
  • Siemens Healthineers
  • Becton, Dickinson, and Company
  • Hoffmann-LA Roche Ltd
  • T2 Biosystems, Inc.
  • Response Biomedical Corp.
  • BioMerieux SA
  • Immunexpress Inc. (LIST NOT EXHAUSTIVE)

第 14 章：附录

简介目录
Product Code: CD1257

Report Overview

The Global Sepsis Diagnostics Market reached US$ 710.13 million in 2023 and is expected to reach US$ 1,435.24 million by 2031, growing at a CAGR of 9.5% during the forecast period 2024-2031.

Sepsis is a life-threatening illness that occurs when the body's immune system overreacts to an infection, causing organ malfunction. The body's response damages its tissues and organs, which can result in shock, multiple organ failure, and even death if not detected and treated swiftly.

Blood tests and other lab tests such as urine, liquid from the wound, mucus, and saliva from the respiratory tract are performed to diagnose the condition.

Market Dynamics: Drivers & Restraints

The growing burden of infectious diseases

If infectious infections are not detected and treated promptly, they can develop into serious conditions such as sepsis. As a result, there is a greater emphasis on early diagnosis of infections that could develop into sepsis. Diagnostic tests for sepsis assist healthcare providers in detecting the condition early, allowing for appropriate intervention and management. HAIs are hospital-acquired infections that can significantly contribute to sepsis cases.

As healthcare-associated infections continue to rise, there is a greater need for precise diagnostic tools to monitor patients and diagnose sepsis early in these settings.

In Europe, the burden of the six most frequent HAIs was calculated to be twice the burden of 32 other infectious diseases altogether, in terms of disability and premature mortality.

Additionally, according to research published by 2023 Balasubramanian et al., an estimated 136 million cases of healthcare-associated antibiotic-resistant infections occur worldwide every year. Thus, the increasing burden of infectious diseases is expected to drive the market growth.

High Cost of Diagnostic Tools

Automated diagnostic instruments and biomarker tests can be costly. High upfront expenses could result in a slower overall adoption rate among medical facilities. This directly translates into slower growth in the sepsis diagnostics market. Despite these limitations, hospitals will continue to use older, less expensive methods.

Segment Analysis

The global sepsis diagnostic market is segmented based on product, technology, diagnostic method, pathogen, end-user and region.

Blood Culture Media segment is expected to dominate the market growth

Blood culture media is expected to be the dominant segment in the sepsis diagnostics market. Blood culture media is a less expensive diagnostic technique than other approaches such as molecular diagnostics. Blood culture media is readily accessible and simple in most therapeutic settings.

While more rapid approaches are emerging, blood cultures remain the accepted standard for identifying the specific pathogens causing sepsis since they allow for the growth and identification of bacteria or fungi. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to hold a significant position in the sepsis diagnostic market share

North America is expected to dominate the sepsis diagnostic market owing to the increasing prevalence of sepsis and the technological advancements in sepsis diagnosis such as advanced diagnostic facilities and high adoption rates of medical technologies are expected to drive the market growth in the region. The medical diagnostic companies in the region are introducing several tests and the required sepsis diagnostic tools which could help in driving the market growth.

Foe instance, in August 2023, Medical diagnostic company Cytovale commercially introduced its new diagnostic tool, the IntelliSep sepsis test, in the US. The test was launched following 510(k) clearance from the US Food and Drug Administration in December 2022.

Additionally, on April 3, 2024, Prenosis, Inc. received the U.S. Food and Drug Administration (FDA) approval of the marketing authorization for the Sepsis ImmunoScoreTM using the De Novo pathway. The Sepsis ImmunoScoreTM is an artificial intelligence/machine learning software as a medical device (AI SaMD) to guide rapid diagnosis and prediction of sepsis. Thus, the above factors are expected to hold the region in the dominant position.

Market Segmentation

By Product

Instruments

Software

Blood Culture Media

Assays & Reagents

Others

By Technology

Flow Cytometry

Microbiology

Biomarkers

Molecular Diagnostics

Microfluidics

Others

By Pathogen

Automated Diagnostics

Conventional Diagnostics

By Diagnostic Method

Fungal Sepsis

Bacterial Sepsis

Gram-Positive Bacterial Sepsis

Gram-Negative Bacterial Sepsis

Other Pathogens

By End-User

Hospitals

Pathology & Reference Laboratories

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

Middle East and Africa

Competitive Landscape

The major global players in the market include Thermo Fisher Scientific Inc., Bruker Corporation, Merck Millipore, Siemens Healthineers, Becton, Dickinson, and Company, Hoffmann-LA Roche Ltd, T2 Biosystems, Inc., Response Biomedical Corp., BioMerieux SA, and Immunexpress Inc. among others.

Key Developments

On April 18, 2023, Carle Illinois College of Medicine faculty member Rashid Bashir received marketing approval from the Food and Drug Administration for A new AI tool for sepsis diagnosis developed from research.

On November 27, 2023, Asep Medical Holdings Inc. secured patent approval in the US for its AI-based sepsis diagnostic technology, SepsetER.

Why Purchase the Report?

To visualize the global Sepsis Diagnostic market segmentation based on Product, Technology, Diagnostic Method, Pathogen and End-User and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of Sepsis Diagnostic market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global Sepsis Diagnostic market report would provide approximately 53 tables, 47 figures and 176 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Diagnostic Method
  • 3.4. Snippet by Technology
  • 3.5. Snippet by End-User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing burden of infectious diseases
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of diagnostic tools
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Product

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 6.1.2. Market Attractiveness Index, By Product
  • 6.2. Instruments *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Software
  • 6.4. Blood Culture Media
  • 6.5. Assays & Reagents
  • 6.6. Others

7. By Technology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 7.1.2. Market Attractiveness Index, By Technology
  • 7.2. Flow Cytometry*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Microbiology
  • 7.4. Biomarkers
  • 7.5. Molecular Diagnostics
  • 7.6. Microfluidics
  • 7.7. Others

8. By Diagnostic Method

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 8.1.2. Market Attractiveness Index, By Diagnostic Method
  • 8.2. Automated Diagnostics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Conventional Diagnostics

9. By Pathogen

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
    • 9.1.2. Market Attractiveness Index, By Pathogen
  • 9.2. Fungal Sepsis*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Bacterial Sepsis
    • 9.3.1. Gram-Positive Bacterial Sepsis
    • 9.3.2. Gram-Negative Bacterial Sepsis
  • 9.4. Other Pathogens

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Pathology & Reference Laboratories
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
      • 11.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 11.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
      • 11.2.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
      • 11.2.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.4.1. U.S.
      • 11.2.4.2. Canada
      • 11.2.4.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
      • 11.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 11.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
      • 11.3.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.5.1. Germany
      • 11.3.5.2. UK
      • 11.3.5.3. France
      • 11.3.5.4. Italy
      • 11.3.5.5. Spain
      • 11.3.5.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
      • 11.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 11.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
      • 11.4.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.5.1. Brazil
      • 11.4.5.2. Argentina
      • 11.4.5.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
      • 11.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 11.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
      • 11.5.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.5.1. China
      • 11.5.5.2. India
      • 11.5.5.3. Japan
      • 11.5.5.4. Australia
      • 11.5.5.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
      • 11.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
      • 11.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
      • 11.6.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
      • 11.6.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Thermo Fisher Scientific Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Bruker Corporation
  • 13.3. Merck Millipore
  • 13.4. Siemens Healthineers
  • 13.5. Becton, Dickinson, and Company
  • 13.6. Hoffmann-LA Roche Ltd
  • 13.7. T2 Biosystems, Inc.
  • 13.8. Response Biomedical Corp.
  • 13.9. BioMerieux SA
  • 13.10. Immunexpress Inc. (LIST NOT EXHAUSTIVE)

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us